All Shows Feed | Horse Radio Network

Short Summary: Dr. Holly Helbig and Dr. David Levine describe how they use SAA and other biomarkers to spot infection early, guide treatment, support biosecurity, and monitor horses in real time.Landing page copy: Acute phase proteins such as serum amyloid A (SAA) give veterinarians an early look at inflammation, infection, and how a horse responds to treatment. In this Equine Innovators episode, we dig into how SAA and other key biomarkers guide everyday decisions—from biosecurity on busy farms and showgrounds to managing postoperative cases, colic, and foal exams.Host Stephanie Church, editorial director at The Horse, talks with Dr. Holly Helbig of Zoetis and Dr. David Levine from the University of Pennsylvania’s New Bolton Center about when they reach for SAA, how it compares with fibrinogen and white blood cell counts, and why serial testing often matters more than any single number. They share stall-side and hospital protocols, real-world case examples, and ways biomarker trends support smarter antimicro